

30th January, 2026

To, The General Manager Department of Corporate Services BSE Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. Ref.: Scrip Code No. : 540701 (Equity) : 975834, 976560 and 977467 (Debt)	To, The Manager, Listing Department, National Stock Exchange of India Ltd. “Exchange Plaza”, C-1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. Ref. : (i) Symbol – DCAL (ii) Series – EQ
--	--

SUB: INTIMATION OF CONFERENCE CALL

Dear Sir,

This is to inform that pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, the Company has arranged Conference Call with Investors on Wednesday, 4th February, 2026 at 15:00 hrs. (IST) to discuss the financial result and performance of the Company for the third quarter ended on 31st December, 2025.

The details of Conference Call are attached herewith.

Kindly take the same on your record.

Thanking You,
Yours faithfully,

For, Dishman Carbogen Amcis Limited**Shrima Dave**
Company Secretary

Encl.: As Above



Dishman Carbogen Amcis Limited to announce its Q3 & 9MFY26 results on 03 February 2026. The management of the company to host

Q3 & 9MFY26 Earnings Conference Call on

04 February 2026 at 15:00hrs - 16:00hrs, IST



Primary Numbers

086 3416 8816 /
086 4536 7276

International Toll-Free Numbers

USA - 18773870849 | Singapore - 8001011941
UK - 08000163439 | Hong Kong - 800903171

International Participation PIN No.: 6197290#

Pre-Registration Facility

(Express Join with DiamondPass™ to avoid long queue and save time)

[Click here](#) to pre-register for the call and dial in directly without waiting for the operator.

Management Represented by:

Mr. Harshil Dalal

Global CFO

Mr. Stephan Fritschi

Chief Executive Officer, Carbogen Amcis Entities

About Dishman Carbogen Amcis Limited

Established in 1983, Dishman Carbogen Amcis Limited is a fully integrated CDMO (Contract Development and Manufacturing Organisation) company with strong capabilities right from process research & development to late stage clinical and commercial manufacturing and supply of API to innovator pharmaceutical companies. The company has global presence with development and manufacturing sites in Switzerland, UK, France, Netherlands, India, and China.

The company provides end-to-end integrated high-value niche CDMO offering and has comprehensive product offerings which include APIs, High Potent APIs, Intermediates, Phase Transfer Catalysts, Vitamin D Analogues, Cholesterol, Lanolin-related products, Antiseptic and Disinfectant formulations.

For details, please visit www.imdcal.com.

For details please contact:

Harshil Dalal

Global CFO

P: +91 22 22867597

E: harshil.dalal@dishmangroup.com

Krishna Patel

Ernst & Young LLP

P: +91 9998236402

E: krishna.patel2@in.ey.com